Introduction. Reboxetine: a new selective antidepressant for the treatment of depression.
Montgomery
S A
SA
Imperial College of Medicine at St Mary's, London, England, UK.
Schatzberg
A F
AF
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000502:physiology; D000077593:Reboxetine; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine; D009638:Norepinephrine